Merck’s life science business signed the MoU with MOTIE and Daejeon City for the new bioprocessing production facility. Credit: Merck KGaA, Darmstadt, Germany and/or its affiliates.

Merck’s Life Science business has entered into a non-binding memorandum of understanding (MOU) with the South Korean Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City to establish a new bioprocessing production facility, to be known as the Asia Pacific BioProcessing Production Centre.

It will be situated in South Korea’s Daejeon City and will help biotech and pharmaceutical clients in the region with commercial production.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Merck also plans to collaborate with the Daejeon government to offer help to biotech firms in the Daedeok research complex in Daejeon, and to forge partnerships in bio-research with major Korean universities.

Merck executive board member and life science CEO Matthias Heinzel stated: “South Korea is an emerging global leader in the biotech industry, and this MoU demonstrates Merck’s commitment to the region by working closely with the government to better support our customers.

“The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.”

Merck is a science and technology firm with operations across life science, healthcare and the electronics industries.

Daejeon mayor Jang Woo Lee stated: “Daejeon is the birthplace of the Korean biotech industry. Today it’s where companies, big and small, are intensely focused on technological innovation and talent development to bring new and novel therapies to market.

“Together with Merck, this planned investment cooperation will help support Daejeon’s growth to become a world-class biotech hub.”